Eur Urol:前列腺癌的保守治疗,观察等待or主动监测?

2017-08-25 fengxiangxin MedSci原创

目前,越来越多的前列腺癌采用保守治疗策略。然而,尚没有对何种随访为最佳随访策略达成共识。因此,研究者欲从预期寿命和生活质量两个方面比较观察等待和主动监测两种随访策略带来的差异。

目前,越来越多的前列腺癌采用保守治疗策略。然而,尚没有对何种随访为最佳随访策略达成共识。因此,研究者欲从预期寿命和生活质量两个方面比较观察等待和主动监测两种随访策略带来的差异。

研究者为50岁以后诊断为局限性前列腺癌并选择保守治疗(观察等待或主动监测)的美国男性创建了一个马尔可夫模型,对他们使用不同的监测方式(每3-6月检测前列腺特异性抗原、每1-5年前列腺活检或磁共振成像检查)。主要结果是生命年和质量调整生命年(QALYs),次要结果包括根治性治疗、转移和前列腺癌死亡。

与观察等待相比,所有的主动监测策略都给患者带来了更多的生命年。主动监测和观察等待相比,前列腺癌死亡的终生风险为5.42% vs 6.40%,前列腺癌转移的终生风险为8.72% vs 10.30%。

除了确诊时年龄>65岁的队列和出现治疗相关的长期并发症两种情况之外,主动监测为患者带来了更多的质量调整生命年(QALYs)。

依患者是否重视短期利益胜过长期利益(时间偏好)在很大程度上决定了后续的首选治疗策略,不同的主动监测策略中分别有30-41%的患者在10年内选择行根治性治疗。延长活检间隔1-5后,患者的生命年略有减少,有0.26的QALYs差异。

相比观察等待,主动监测更多的延长了患者的寿命,尤其是对那些具有较高风险特征的男性患者。但是,这类患者中的大部分最终还是接受了治疗,由此带来的生活质量下降抵消了主动监测带来的收益。

原始出处:


本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1506577, encodeId=5f8f15065e7c1, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508905, encodeId=d4cf150890598, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237128, encodeId=efe823e12829, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Aug 25 23:17:15 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237039, encodeId=ad4123e03910, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 25 19:38:28 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237024, encodeId=09ce23e02411, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Fri Aug 25 16:50:24 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1506577, encodeId=5f8f15065e7c1, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508905, encodeId=d4cf150890598, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237128, encodeId=efe823e12829, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Aug 25 23:17:15 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237039, encodeId=ad4123e03910, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 25 19:38:28 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237024, encodeId=09ce23e02411, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Fri Aug 25 16:50:24 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1506577, encodeId=5f8f15065e7c1, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508905, encodeId=d4cf150890598, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237128, encodeId=efe823e12829, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Aug 25 23:17:15 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237039, encodeId=ad4123e03910, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 25 19:38:28 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237024, encodeId=09ce23e02411, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Fri Aug 25 16:50:24 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 130****4638

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1506577, encodeId=5f8f15065e7c1, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508905, encodeId=d4cf150890598, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237128, encodeId=efe823e12829, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Aug 25 23:17:15 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237039, encodeId=ad4123e03910, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 25 19:38:28 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237024, encodeId=09ce23e02411, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Fri Aug 25 16:50:24 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 131****1460

    学习了受益匪浅.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1506577, encodeId=5f8f15065e7c1, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508905, encodeId=d4cf150890598, content=<a href='/topic/show?id=8e1e2e181f4' target=_blank style='color:#2F92EE;'>#保守治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27181, encryptionId=8e1e2e181f4, topicName=保守治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d710016703, createdName=cmsvly, createdTime=Sun Aug 27 07:34:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237128, encodeId=efe823e12829, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Fri Aug 25 23:17:15 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237039, encodeId=ad4123e03910, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Aug 25 19:38:28 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237024, encodeId=09ce23e02411, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Fri Aug 25 16:50:24 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 fengxiangxin301

    不错

    0

相关资讯

Sci Rep:肌凝蛋白同种型在转移前列腺癌中的表达刺激了细胞侵入

在转移过程中,肿瘤细胞迁移出它们原来的组织入侵到其他器官中。外泌体和金属蛋白酶的分泌对细胞外基质重塑是必需的,从而促使通过组织障碍的成功迁移。转移性前列腺癌可以由稀有的分子马达肌凝蛋白IC的同种型A的表达来区分,然而,该同种型的功能仍旧未知。最近,有研究人员进行的研究表明该同种型可以利于前列腺癌细胞侵入的运动性。另外,研究人员还发现该同种型与包含金属蛋白酶的外泌体有联系并且刺激它们的分泌。尽管数据

Nat Med:肿瘤特异性SPOP突变与BET治疗敏感性差异

研究揭示了肿瘤源性突变差异,即不同肿瘤的相同结构域突变导致不同的药物敏感性

Eur Urol:mCRPC患者外周全血中的AR-V7预测治疗反应。

以往的研究已经证明,转移性去势抵抗性前列腺癌(mCRPC)患者循环肿瘤细胞(CTCs)中表达雄激素受体剪接变异体7(AR-V7)可预测其对阿比特龙(abiraterone)或恩杂鲁胺(enzalutamide)的治疗反应较差。

Cancer Res:PADI2调控的瓜氨酸化促进了前列腺癌进展

去雄抵抗性前列腺癌(CRPC)在长期雄激素阻断治疗后的发病仍旧是治疗前列腺癌(PCa)的一个主要障碍。之前的研究表明,肽酰精氨酸脱亚氨酶PADI2在慢性炎症反应疾病中和癌症中具有作用。最近,有研究人员阐释了PADI2是一个雄激素抑制基因,并且在CRPC中表达上调。PADI2的表达对PCa细胞的生存和细胞周期的进展是需要的。在体内和体外试验的雄激素阻断或者去势难治性条件下,PADI2可以促进PCa细

Eur Urol:新型血检预测癌症的耐药性,让癌症患者少走冤枉路

当细菌产生抗药性的时候,这些药物就会变得无效。同样,肿瘤细胞也是如此,它们会针对特定的药物逐渐改变,产生耐药性,这对于癌症的治疗时非常关键的,如果医生可以尽早了解这一情况,就可以做出相应的应对措施,来自慕尼黑工业大学的研究人员研发的血液检测可以用来预测晚期前列腺癌患者的耐药性。

CLIN CANCER RES:前列腺癌患者前列腺内阿比特龙水平和SLCO基因变化与病理反应有关

SLCO基因改变会影响细胞类固醇摄取,与前列腺癌结局有关。CYP17A抑制剂阿比特龙也有类固醇结构,SLCO编码的受体可能影响其转运,SLCO基因改变可能会影响细胞内阿比特龙水平并影响其疗效。CLIN CANCER RES近期发表了一篇文章,研究SLCO基因是否对阿比特龙摄取产生影响。